Method for detecting castration-resistant prostate cancer and detection reagent
US11604194B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 23, 2017 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | May 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/09
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.